Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19

Yıl: 2023 Cilt: 5 Sayı: 2 Sayfa Aralığı: 94 - 105 Metin Dili: İngilizce DOI: 10.36519/idcm.2023.206 İndeks Tarihi: 05-07-2023

Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19

Öz:
Objective: This study aimed to define the predictors of critical illness development within 28 days postadmission during the first wave of the COVID-19 pandemic. Materials and Methods: We conducted a prospective cohort study including 477 PCR-positive COVID-19 patients admitted to a tertiary care hospital in Istanbul from March 12 to May 12, 2020. Results: The most common presenting symptoms were cough, dyspnea, and fatigue. Critical illness developed in 45 (9.4%; 95% CI=7.0%-12.4%) patients. In the multivariable analysis, age (hazard ratio (HR)=1.05, p <0.001), number of comorbidities (HR=1.33, p=0.02), procalcitonin ≥0.25 μg/L (HR=2.12, p=0.03) and lactate dehydrogenase (LDH) ≥350 U/L (HR=2.04, p=0.03) were independently associated with critical illness development. The World Health Organization (WHO) ordinal scale for clinical improvement on admission was the strongest predictor of critical illness (HR=4.15, p<0.001). The patients hospitalized at the end of the study period had a much better prognosis compared to the patients hospitalized at the beginning (HR=0.14; p=0.02). The C-index of the model was 0.92. Conclusion: Age, comorbidity number, the WHO scale, LDH, and procalcitonin were inde- pendently associated with critical illness development. Mortality from COVID-19 seemed to be decreasing as the first wave of the pandemic advanced.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1 COVID-19 Weekly Situation Report 13/07/2020 – 19/07/2020 [Internet]. Ankara: Republic of Turkey Ministry of Health. [cit- ed October 17, 2020]. Available from: https://dosyamerkez. saglik.gov.tr/Eklenti/38021,covid-19-weekly-situation-re- port---29-weekpdf.pdf?0&_tag1=44DBE7E25D380A645A4780C- 04D8C19C0EF692249
  • 2 Confirmed cases per day in Turkey [Internet]. Geneva: World Health Organization (WHO). [cited February 5, 2022]. Available from: https://covid19.who.int/region/euro/country/tr
  • 3 Demirbilek Y, Pehlivantürk G, Özgüler ZÖ, Alp Meşe E. COVID-19 outbreak control, example of ministry of health of Turkey. Turk J Med Sci. 2020;50(SI-1):489-94. [CrossRef]
  • 4 COVID-19 Guideline [Internet]. Ankara: Republic of Turkey Ministry of Health. [cited Oct 17, 2020]. Available from: https:// covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html
  • 5 Shivalkar S, Pingali MS, Verma A, Singh A, Singh V, Paital B, et al. Outbreak of COVID-19: A detailed overview and its conse- quences. Adv Exp Med Biol. 2021;1353:23-45. [CrossRef]
  • 6 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324(8):782-93. [CrossRef]
  • 7 Wu Z, McGoogan JM. Characteristics of and important les- sons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. [CrossRef]
  • 8 Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, et al. Acute complications and mortality in hospitalized pa- tients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020;24(1):389. [CrossRef]
  • 9 Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and progno- sis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. Update in: BMJ. 2021;372:n236. Erratum in: BMJ. 2020;369:m2204. [CrossRef]
  • 10 Anesi GL, Halpern SD, Delgado MK. Covid-19 related hospital admissions in the United States: needs and outcomes. BMJ. 2020;369:m2082. [CrossRef]
  • 11 Weissman GE, Crane-Droesch A, Chivers C, Luong T, Hanish A, Levy MZ, et al. Locally informed simulation to predict hospi- tal capacity needs during the COVID-19 pandemic. Ann Intern Med. 2020;173(1):21-8. [CrossRef]
  • 12 COVID-19 therapeutic trial synopsis [Internet]. Geneva: World Health organization (WHO). [cited June 01, 2022]. Available from: https://www.who.int/publications/i/item/covid-19-ther- apeutic-trial-synopsis
  • 13 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consen- sus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-10. [CrossRef]
  • 14 Xu PP, Tian RH, Luo S, Zu ZY, Fan B, Wang XM, et al. Risk fac- tors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020;10(14):6372-83. [CrossRef]
  • 15 Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-4. [CrossRef]
  • 16 Aguiar M, Stollenwerk N. Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe. Public Health. 2020;188:18-20. [CrossRef]
  • 17 Paliani U, Cardona A. COVID-19 and hydroxychloroquine: Is the wonder drug failing? Eur J Intern Med. 2020;78:1-3. [Cross- Ref]
  • 18 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. [CrossRef]
  • 19 Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VC, Ed- wards KM, et al. IDSA Guidelines on the Treatment and Man- agement of Patients with COVID-19; Version 10.2.0. [Internet]. Arlington: Infectious Diseases Society of America 2022; Ver- sion 10.2.0. [cited February 20, 2023]. Available from: https:// www.idsociety.org/practice-guideline/covid-19-guideline- treatment-and-management/
  • 20 Rivera-Izquierdo M, Del Carmen Valero-Ubierna M, R-delAmo JL, Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A, et al. Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospital- ized patients: A retrospective observational study. PLoS One. 2020;15(6):e0235107. [CrossRef]
  • 21 Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admis- sion and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. [CrossRef]
  • 22 Bhargava A, Sharma M, Akagi E, Szpunar SM, Saravolatz L. Predictors for in-hospital mortality from coronavirus disease 2019 (COVID-19) infection among adults aged 18-65 years. In- fect Control Hosp Epidemiol. 2021;42(6):772-5. [CrossRef]
  • 23 Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. [Cross- Ref]
  • 24 Türkiye Sağlık Araştırması [Internet]. Ankara: Turkish Sta- tistic Institute. [cited Oct 17, 2020]. Available from: https:// data.tuik.gov.tr/Bulten/Index?p=Turkiye-Saglik-Arastirma- si-2019-33661
  • 25 Ioannou GN, Locke E, Green P, Berry K, O’Hare AM, Shah JA, et al. Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. JAMA Netw Open. 2020;3(9):e2022310. [CrossRef]
  • 26 Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al; China Medical Treatment Expert Group for COVID-19. Development and vali- dation of a clinical risk score to predict the occurrence of criti- cal illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-9. [CrossRef]
  • 27 Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coro- navirus disease 2019-a multi-centre observational study. Clin Microbiol Infect. 2020;26(9):1242-7. [CrossRef]
  • 28 Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A tool for early pre- diction of severe coronavirus disease 2019 (COVID-19): A mul- ticenter study using the risk nomogram in Wuhan and Guang- dong, China. Clin Infect Dis. 2020;71(15):833-40. [CrossRef]
  • 29 Allenbach Y, Saadoun D, Maalouf G, Vieira M, Hellio A, Boddaert J, et al; DIMICOVID. Development of a multivariate prediction model of intensive care unit transfer or death: A French pro- spective cohort study of hospitalized COVID-19 patients. PLoS One. 2020;15(10):e0240711. [CrossRef]
  • 30 Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the an- ticoagulation forum. J Thromb Thrombolysis. 2020;50(1):72-81. [CrossRef]
  • 31 Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfal- terer W, et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-27.e19. [CrossRef]
  • 32 Doidge JC, Gould DW, Ferrando-Vivas P, Mouncey PR, Thomas K, Shankar-Hari M, et al. Trends in intensive care for patients with COVID-19 in England, Wales, and Northern Ireland. Am J Respir Crit Care Med. 2021;203(5):565-74. [CrossRef]
APA Sili U, AY N, Topuzoğlu A, Bilgin H, Tukenmez Tigen E, ERTURK SENGEL B, Yağcı Çağlayık D, Balcan B, Kocakaya D, OLGUN S, Gul F, Bilgili B, Can Sarınoğlu R, karahasan a, MULAZIMOGLU L, Eryüksel S, odabasi z, Direskeneli H, KARAKURT S, Cinel I, KORTEN V (2023). Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. , 94 - 105. 10.36519/idcm.2023.206
Chicago Sili Uluhan,AY NADIYE PINAR,Topuzoğlu Ahmet,Bilgin Huseyin,Tukenmez Tigen Elif,ERTURK SENGEL Buket,Yağcı Çağlayık Dilek,Balcan Baran,Kocakaya Derya,OLGUN Sehnaz,Gul Fethi,Bilgili Beliz,Can Sarınoğlu Rabia,karahasan aysegul,MULAZIMOGLU LUTFIYE,Eryüksel Semiha Emel,odabasi zekaver,Direskeneli Haner,KARAKURT SAİT,Cinel Ismail,KORTEN VOLKAN Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. (2023): 94 - 105. 10.36519/idcm.2023.206
MLA Sili Uluhan,AY NADIYE PINAR,Topuzoğlu Ahmet,Bilgin Huseyin,Tukenmez Tigen Elif,ERTURK SENGEL Buket,Yağcı Çağlayık Dilek,Balcan Baran,Kocakaya Derya,OLGUN Sehnaz,Gul Fethi,Bilgili Beliz,Can Sarınoğlu Rabia,karahasan aysegul,MULAZIMOGLU LUTFIYE,Eryüksel Semiha Emel,odabasi zekaver,Direskeneli Haner,KARAKURT SAİT,Cinel Ismail,KORTEN VOLKAN Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. , 2023, ss.94 - 105. 10.36519/idcm.2023.206
AMA Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. . 2023; 94 - 105. 10.36519/idcm.2023.206
Vancouver Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. . 2023; 94 - 105. 10.36519/idcm.2023.206
IEEE Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V "Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19." , ss.94 - 105, 2023. 10.36519/idcm.2023.206
ISNAD Sili, Uluhan vd. "Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19". (2023), 94-105. https://doi.org/10.36519/idcm.2023.206
APA Sili U, AY N, Topuzoğlu A, Bilgin H, Tukenmez Tigen E, ERTURK SENGEL B, Yağcı Çağlayık D, Balcan B, Kocakaya D, OLGUN S, Gul F, Bilgili B, Can Sarınoğlu R, karahasan a, MULAZIMOGLU L, Eryüksel S, odabasi z, Direskeneli H, KARAKURT S, Cinel I, KORTEN V (2023). Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. Infectious diseases and clinical microbiology (Online), 5(2), 94 - 105. 10.36519/idcm.2023.206
Chicago Sili Uluhan,AY NADIYE PINAR,Topuzoğlu Ahmet,Bilgin Huseyin,Tukenmez Tigen Elif,ERTURK SENGEL Buket,Yağcı Çağlayık Dilek,Balcan Baran,Kocakaya Derya,OLGUN Sehnaz,Gul Fethi,Bilgili Beliz,Can Sarınoğlu Rabia,karahasan aysegul,MULAZIMOGLU LUTFIYE,Eryüksel Semiha Emel,odabasi zekaver,Direskeneli Haner,KARAKURT SAİT,Cinel Ismail,KORTEN VOLKAN Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. Infectious diseases and clinical microbiology (Online) 5, no.2 (2023): 94 - 105. 10.36519/idcm.2023.206
MLA Sili Uluhan,AY NADIYE PINAR,Topuzoğlu Ahmet,Bilgin Huseyin,Tukenmez Tigen Elif,ERTURK SENGEL Buket,Yağcı Çağlayık Dilek,Balcan Baran,Kocakaya Derya,OLGUN Sehnaz,Gul Fethi,Bilgili Beliz,Can Sarınoğlu Rabia,karahasan aysegul,MULAZIMOGLU LUTFIYE,Eryüksel Semiha Emel,odabasi zekaver,Direskeneli Haner,KARAKURT SAİT,Cinel Ismail,KORTEN VOLKAN Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. Infectious diseases and clinical microbiology (Online), vol.5, no.2, 2023, ss.94 - 105. 10.36519/idcm.2023.206
AMA Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. Infectious diseases and clinical microbiology (Online). 2023; 5(2): 94 - 105. 10.36519/idcm.2023.206
Vancouver Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19. Infectious diseases and clinical microbiology (Online). 2023; 5(2): 94 - 105. 10.36519/idcm.2023.206
IEEE Sili U,AY N,Topuzoğlu A,Bilgin H,Tukenmez Tigen E,ERTURK SENGEL B,Yağcı Çağlayık D,Balcan B,Kocakaya D,OLGUN S,Gul F,Bilgili B,Can Sarınoğlu R,karahasan a,MULAZIMOGLU L,Eryüksel S,odabasi z,Direskeneli H,KARAKURT S,Cinel I,KORTEN V "Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19." Infectious diseases and clinical microbiology (Online), 5, ss.94 - 105, 2023. 10.36519/idcm.2023.206
ISNAD Sili, Uluhan vd. "Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19". Infectious diseases and clinical microbiology (Online) 5/2 (2023), 94-105. https://doi.org/10.36519/idcm.2023.206